Quantification of dopamine transporter by 123I-PE2I SPECT and the noninvasive Logan graphical method in Parkinson's disease

Caroline Prunier, Pierre Payoux, Denis Guilloteau, Sylvie Chalon, Bruno Giraudeau, Cynthia Majorel, Mathieu Tafani, Erwan Bezard, Jean-Paul Esquerré, Jean-Louis Baulieu
2003 Journal of Nuclear Medicine  
(E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methyl-phenyl) nortropane (PE2I), a cocaine analog, is a new, highly specific tracer for imaging dopamine transporter labeled with (123)I for in vivo SPECT. Its reversible binding on dopamine transporter and its rapid kinetics allow quantification of its binding potential according to a 3-compartment model. For quantification of distribution volume of reversible tracer, Logan developed a noninvasive and graphical method that allows accurate
more » ... estimation of binding potential. In this study, we performed (123)I-PE2I SPECT on healthy volunteers and patients with Parkinson's disease (PD) to validate the Logan graphical method for quantification of (123)I-PE2I binding and to analyze the relationship between (123)I-PE2I SPECT and clinical features of this frequent degenerative disease.
pmid:12732666 fatcat:atgyhwl4nbbd7l4rxn5t34mjxi